Zacks Research Issues Positive Estimate for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Research analysts at Zacks Research upped their Q2 2026 earnings per share estimates for Prestige Consumer Healthcare in a research note issued on Monday, June 16th. Zacks Research analyst R. Department now anticipates that the company will earn $1.19 per share for the quarter, up from their prior estimate of $1.18. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q4 2026 earnings at $1.29 EPS, FY2026 earnings at $4.73 EPS and Q4 2027 earnings at $1.25 EPS.

Other research analysts also recently issued research reports about the company. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 17th. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of "Moderate Buy" and a consensus price target of $93.33.

Prestige Consumer Healthcare Stock Down 0.0%

PBH stock opened at $83.62 on Wednesday. Prestige Consumer Healthcare has a fifty-two week low of $64.63 and a fifty-two week high of $90.04. The business's 50-day moving average is $83.85 and its two-hundred day moving average is $82.54. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.82 and a current ratio of 4.20. The company has a market cap of $4.13 billion, a price-to-earnings ratio of 19.49, a P/E/G ratio of 2.51 and a beta of 0.45.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The company had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. During the same period last year, the firm posted $1.02 earnings per share. Prestige Consumer Healthcare's revenue was up 7.0% compared to the same quarter last year.

Institutional Trading of Prestige Consumer Healthcare

A number of large investors have recently added to or reduced their stakes in the company. Kayne Anderson Rudnick Investment Management LLC increased its stake in Prestige Consumer Healthcare by 45.3% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company's stock worth $135,903,000 after acquiring an additional 493,199 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Prestige Consumer Healthcare by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company's stock valued at $105,342,000 after acquiring an additional 21,951 shares during the period. Invesco Ltd. boosted its holdings in Prestige Consumer Healthcare by 24.7% during the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock valued at $113,635,000 after acquiring an additional 261,537 shares during the period. Congress Asset Management Co. boosted its holdings in Prestige Consumer Healthcare by 9.1% during the 1st quarter. Congress Asset Management Co. now owns 991,580 shares of the company's stock valued at $85,246,000 after acquiring an additional 82,838 shares during the period. Finally, Westwood Holdings Group Inc. boosted its holdings in Prestige Consumer Healthcare by 7.1% during the 1st quarter. Westwood Holdings Group Inc. now owns 861,282 shares of the company's stock valued at $74,044,000 after acquiring an additional 56,802 shares during the period. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.